Week in Review: GuaHao Raises $395 Million for China Internet Healthcare

GuaHao.com, a Hangzhou online healthcare portal, completed a $394 million financing round, led by Hillhouse Capital and Goldman Sachs; Genovate Biotech of Taiwan began construction of the first phase of a $1 billion China insulin manufacturing project in Changzhou; CASI Pharma, a US-China biopharma, raised $25 million in a secondary offering for clinical trials; Ativa Medical of Minneapolis completed a $15 million B round from China investors for its diagnostic device; Zai Lab, a two-year old Shanghai biotech, in-licensed global rights to a mAb aimed at autoimmune and inflammatory diseases; Lee's Pharm of Hong Kong in-licensed greater China rights to a novel anticoagulant from California-based Armetheon; Shenzhen's BGI signed an agreement with Huawei Technology to develop big data storage systems for genomic research; and RuiYi, a San Diego-Shanghai biotech, began a Phase I trial of its novel anti-IL-6 cytokine mAb as a treatment for rheumatoid arthritis. More details.... Stock Symbols: (TWO: 4130) (NSDQ: CASI) (HK: 0950) Share this with colleagues: // //